Categories

#PAHOStrategicFund ensures access to diabetes-related medicines through its extensive portfolio of products in the Region. Long-acting insulin analogues and Glicazide

#PAHOStrategicFund ensures access to diabetes-related medicines through its extensive portfolio of products in the Region.

Long-acting insulin analogues and Glicazide are now offered through our procurement mechanisms.

Visit for more information: paho.org/en/paho-strate… https://t.co/PBj0hQJ66V

 
Categories

Important risk factors for #diabetes Type 2, include obesity & physical inactivity, which are higher in the Americas than anywhere

Important risk factors for #diabetes Type 2, include obesity & physical inactivity, which are higher in the Americas than anywhere else in the world.

This #WorldDiabetesDay, learn more about how to limit these risk factors to prevent diabetes ➡️ paho.org/en/campaigns/w… https://t.co/xoFukY2feB

 
Categories

Insulet Issues a Nationwide Voluntary Medical Device Correction for the Omnipod® 5 Controller

Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), today announced a Medical Device Correction for the Omnipod® 5 Automated Insulin Delivery System because of an issue with the Omnipod 5 Controller charging port and cable. This does not impact the Omnipod 5 Pod, the Omnipod® DASH Insulin M

http://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/insulet-issues-nationwide-voluntary-medical-device-correction-omnipodr-5-controller